Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTA.SA.FAPi
- Development stage
- Preclinical
- Lead developer
- Johannes Gutenberg-University Mainz
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
68Ga-DOTA.SA.FAPi (also known as [68Ga]Ga-DOTA.SA.FAPi) is a gallium-68 labeled, squaric acid (SA)-containing small molecule fibroblast activation protein (FAP) inhibitor. It is designed as a diagnostic radiopharmaceutical for positron emission tomography (PET) imaging of various epithelial malignancies and other conditions characterized by active tissue remodeling, such as arrhythmogenic right ventricular cardiomyopathy (ARVC) and renal fibrosis. The tracer targets fibroblast activation protein alpha (FAP) expressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment. It was developed through a collaboration involving Johannes Gutenberg University Mainz, the All India Institute of Medical Sciences (AIIMS), and PositronPharma.
- Other names
- [68Ga]Ga-DOTA-SA-FAPI[68Ga]Ga-DOTA.SA.FAPI[68Ga]Ga-SA-FAPi68Ga-DOTA-SA-FAPI68Ga-DOTA.SA.FAPI68Ga-SA-FAPiDOTA-SA-FAPIDOTA.SA.FAPIGallium-68 DOTA-SA-FAPIGallium68 DOTA-SA-FAPIGallium 68 DOTA-SA-FAPIGallium-68 DOTA.SA.FAPiGallium68 DOTA.SA.FAPiGallium 68 DOTA.SA.FAPiGallium-68 SA-FAPiGallium68 SA-FAPiGallium 68 SA-FAPi
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on 68Ga-DOTA.SA.FAPi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DOTA.SA.FAPi.